Reduction in pathologically activated TGFβ signaling by ARBs has been demonstrated in disease states such as Marfan syndrome [23, 40, 42], muscle injury [41], autoimmune encephalitis [51], and renal injury [52], with significantly beneficial results. This evidence concerns the gene TGFB1 and Marfan syndrome.